MSD have announced results from its Phase 3, KEYNOTE-522 trial that pathological complete response (pCR) in patients with early triple-negative breast cancer significantly increased from 51.2% in the placebo group to 64.8% for those given Keytruda in combination with chemotherapy.
The author of the study Peter Schmid said “we found a 13.6% difference which is a clinically meaningful benefit” when Keytruda was added to chemotherapy prior to surgery.
